PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) Stock Price, Quote, News & History

Key Statistics

Open

Volume / Avg.

0 / 8.76K

Day Range

- - -

52 Wk Range

0.00 - 0.00

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

Recent PsyBio Therapeutics Corp News

MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views

Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.

Lara Goldstein

EXCLUSIVE: In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical dat

Joana Scopel

Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom

Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S.

Lara Goldstein

Psychedelics Production Methods Expect Further IP Protection With 4 New Patents

Biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed four new U.S. Patent Cooperation Treaty (PCT) applications aiming to convert five provisional patent applications.

Lara Goldstein

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.

Lara Goldstein

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-889.77K

Investing Cash Flow (TTM)

857.36K

Financing Cash Flow (TTM)

964.85K

Free Cash Flow (TTM)

-889.77K

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-23.74K

Valuation Metrics

Enterprise Value

$96.52K

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

Earnings Yield % (TTM)

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$41.09K

Total Cash

$12.37K

Debt to Equity

Issuance of Debt (TTM)

-$41.09K

Repayment of Debt (TTM)

-$41.09K

Key Statistics

Open

Volume / Avg.

0 / 8.76K

Day Range

- - -

52 Wk Range

0.00 - 0.00

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

About

Sector

Health Care

Industry

Biotechnology

PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

PSYBF

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

PSYBF

FAQ

How do I buy PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) stock?

You can purchase shares of PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (OTCEM:PSYBF) through any online brokerage.

View our list of the best stock brokerages

Who are PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) competitors?

There are no as such competitors for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp..

What is the forecast, or price target, for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) stock?

There is no analysis for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. to provide a consensus price target.

What is the current price for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF)?

The stock price for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (OTCEM: PSYBF) is $0.000001 last updated May 13, 2026 at 4:01 PM EDT.

Does PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) pay a dividend?

There are no upcoming dividends for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp..

When is PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (OTCEM:PSYBF) reporting earnings?

PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. does not have any upcoming earnings scheduled.

Is PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) going to split?

There is no upcoming split for PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp..

What sector and industry does PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. (PSYBF) operate in?

PSYBIO THERAPEAUTICS CORP by PsyBio Therapeutics Corp. is in the Health Care sector and Biotechnology industry. They are listed on the OTCEM.